Washington State Expands Access to CBD

By: Heidi Urness, Strategic Legal Counsel at Cultiva Law (@MaryJaneEsquire) Over the weekend, new Washington laws went into effect expanding state licensed marijuana producers’ and processors’ ability to source, utilize, and integrate CBD from a non-licensed source into a CBD product available for sale within the state’s recreational marijuana market. I.      Washington State Expands Access…

The Interstate Transportation of Hemp Plants, Seeds, and CBD

By: Heidi Urness, Strategic Legal Counsel at Cultiva Law (@MaryJaneEsquire) The hemp and hemp-derived CBD industries currently face enormous legal uncertainty. Many clients have questions with regard to the marketing, sale, and transportation of hemp across state lines. Unfortunately, the authorities that define the rights, responsibilities, and liabilities that apply to the hemp industry are currently…

BREAKING: Jeff Sessions Resigns; Michigan Legalizes Cannabis

Photo credit: Matthew T. Nichols for the Department of Justice By: Sam Mendez, Strategic Legal Counsel at Cultiva Law Attorney General Jeff Sessions was forced to resign today, capping the already big news from yesterday’s midterm elections in which Michigan voted to legalize cannabis for recreational use and Utah and Missouri legalized medical marijuana. President Trump quickly appointed Jeff…

BREAKING: WSLCB Drastically Changes Marijuana Infused Edibles Policy

By: Sam Mendez, Strategic Legal Counsel at Cultiva Law On Tuesday, the Washington State Liquor and Cannabis Board (WSLCB) held its regularly-scheduled board meeting where they dropped a bombshell: a large quantity of marijuana infused edibles that have already been approved for production and sale in Washington will no longer be approved. When this new policy is implemented––it…

Some CBD Products Rescheduled by DEA Under Controlled Substances Act

By: Sam Mendez and Heidi Urness, Strategic Legal Counsel at Cultiva Law The Drug Enforcement Administration (DEA) announced last Friday that certain Food and Drug Administration (FDA)-approved drugs that contain cannabidiol (CBD) are properly rescheduled as Schedule V drugs under the Controlled Substances Act (CSA). While this move is far from categorically rescheduling CBD – as…